Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects. - Wikidata - wikimedia - TriplyDB

Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.

Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.

http://www.wikidata.org/entity/Q34560437

about

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells SARConnect: A Tool to Interrogate the Connectivity Between Proteins, Chemical Structures and Activity Data Drug interactions with new and investigational antiretrovirals.Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation HIV-1 antiretroviral resistance: scientific principles and clinical applications Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma.Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals.Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines.Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection.Simplification strategies to reduce antiretroviral drug exposure: progress and prospects.Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.Rilpivirine.Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis.Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.Adipose Tissue in HIV Infection.Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses.Characterizing Class-Specific Exposure-Viral Load Suppression Response of HIV Antiretrovirals Using A Model-Based Meta-Analysis.Impact of food and different meal types on the pharmacokinetics of rilpivirine.Model based design and analysis of phase II HIV-1 trials.From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part II: application to drug development.MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.Anti-retroviral drugs: current state and development in the next decade.From TIBO to Rilpivirine: The Chronicle of the Discovery of the Ideal Nonnucleoside Reverse Transcriptase Inhibitor

P2860

Q26827791-0D215B71-E783-486C-9E7D-0277014E6F05 Q26830730-EDA5C7A9-31B7-4935-80C1-2C67BEE162D0 Q27649731-8AC0DED9-2277-497C-889A-C0FB271D1EAC Q28489076-395C2043-6F2D-4A3E-A87B-E6B34ABA1FD2 Q28548473-31BBC80C-8A30-4D16-A9E5-B0694E1465C5 Q30585642-02CEB57E-55DB-4673-B59E-149F819A7430 Q33801821-7BB94474-ADBA-490C-9474-DF70EAA091E2 Q33826308-96995B30-C854-4D88-9C83-334BC684F22F Q34280466-2876A33A-A808-4202-8B4B-2E03DBA12655 Q34316101-4AC3A263-5318-4E2D-8615-D19FF33206E7 Q35111456-29A48584-AA12-402B-BCCC-B738F24CADDB Q35274822-A3DB0E52-B12F-4CBA-9D3B-DF68BB1F69AF Q35557326-CCF81A72-C4A3-4461-BBD9-AA66A55C6420 Q35567828-63356693-1DE9-4960-A61E-F8D367011E16 Q35894312-EEBEEF0E-E6B6-4022-A857-D62F4DC4B695 Q35939695-F09213CC-1EB1-4880-95DE-2C6A51835804 Q36018903-7E62204C-0A72-4DFF-AE5F-87AD5FCD380D Q36958229-5956C02C-548A-41FF-A350-70F8CF226B44 Q37277829-B21DDFA6-08AA-4F8C-B492-67E2369FDC33 Q37403454-EFDD9736-06DE-40CE-9EC5-74610AE03730 Q37528451-1A914075-D5BE-4682-8C19-58920153ECFE Q37649249-B218AB6D-B0D0-4E39-87B8-ABD5C779CDCA Q37987209-DCBCF087-0FC4-4237-B4BB-053C50F2F4C5 Q38168930-F37DC50B-77F7-457F-8F9C-C56F7A7890AE Q38272654-CD70B795-3765-4C5B-B5DF-38BE17F636FE Q38802093-3571C5F4-9175-4CF4-82B9-DA07C0CA6F2F Q39371494-60D7C35E-95A0-4C3F-ADF5-4E43C43D4E5C Q39760086-1790F342-5F47-416C-86D3-DC2BF35BDE41 Q39771532-33C6BA32-43E0-4DDB-A1B4-16E3C5E40668 Q40038736-A6677879-7F81-452C-86B4-6E5908FC2237 Q40055204-544F7EDF-91D2-4389-B7F1-DD4C2D2A2E4F Q40677725-732917F4-8182-49FD-A22D-3A5BB880D517 Q42261088-3E3B22AE-AA5A-4638-B04E-231644494D8C Q42284705-7BB1E2BF-005C-4E81-82CC-530750427F34 Q46697094-5008D3DB-3EFB-4719-9B4D-DEAC273B56C0 Q47407899-17C3B15D-73E1-4B0E-9C98-F7A151C269A6 Q48145638-ED2CBBC4-4C5E-4472-8363-23DF35C1819D Q49564927-CB8F0B86-10CB-4D2A-9B3A-1E4430587301 Q54222874-EC0FE554-B316-427A-98F1-B519051183E2 Q56786251-03CA5BD7-90FD-4CA7-AA9A-0FCCD189F095

P2860

Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.

http://www.wikidata.org/entity/Q34560437

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Short-term antiviral activity ...... naive HIV-1-infected subjects.

@ast

Short-term antiviral activity ...... naive HIV-1-infected subjects.

@en

Short-term antiviral activity ...... naive HIV-1-infected subjects.

@nl

type

label

Short-term antiviral activity ...... naive HIV-1-infected subjects.

@ast

Short-term antiviral activity ...... naive HIV-1-infected subjects.

@en

Short-term antiviral activity ...... naive HIV-1-infected subjects.

@nl

prefLabel

Short-term antiviral activity ...... naive HIV-1-infected subjects.

@ast

Short-term antiviral activity ...... naive HIV-1-infected subjects.

@en

Short-term antiviral activity ...... naive HIV-1-infected subjects.

@nl

P1433

Q34560437-46E0221A-5C9A-4EEA-9709-083FE5FBEF9D

P1476

Q34560437-F62E9E36-5CEB-4C92-9DF4-D34D276F5481

P2093

Q34560437-079E482F-78AC-458D-B60D-7D8E6CC6307C

Q34560437-1774D2AF-D73E-4685-A06C-859EA94CD31B

Q34560437-3A602F99-5281-4DD1-BFB3-D4CE8A793271

Q34560437-49AD65DA-CF79-43AE-B02B-46B7D43E98C5

Q34560437-583AD04F-115B-4A34-8285-AF582E960E06

Q34560437-68B772CA-2C9F-4385-B4D6-B6F43FC467BD

Q34560437-7AC0DE08-1BD9-4F56-B541-E1CB7B8378D2

Q34560437-B60C745E-A43D-4E4D-B16D-23B64295335D

Q34560437-D8E94B99-1F14-4283-A7C6-DF5EBCA7D8DF

P304

Q34560437-DEE904E1-2652-460A-8CC5-64E618598484

P31

Q34560437-54F19113-F40B-42B4-9FAA-CDCB19E54901

P356

Q34560437-92F8E186-8D47-4252-867D-5B8997907FBC

P407

Q34560437-DB45DBED-7598-4360-8947-34F523C383EB

P433

Q34560437-8A0F5A7C-4EB3-4A47-8530-47F32D9004B2

P478

Q34560437-F9EFC322-18BF-4124-8DFC-6F81CF785A40

P577

Q34560437-FD8A7C2C-3F7E-4469-A363-526396796A9A

P698

Q34560437-07B4EE10-8DC4-4CA9-8D80-21A6FDD61219

P356

01.AIDS.0000242818.65215.BD

P1433

P1476

Short-term antiviral activity ...... naive HIV-1-infected subjects.

@en

P2093

Alexy Yakovlev

http://www.w3.org/2001/XMLSchema#string

Anton L Pozniak

http://www.w3.org/2001/XMLSchema#string

Brian Woodfall

http://www.w3.org/2001/XMLSchema#string

Elena Vinogradova

http://www.w3.org/2001/XMLSchema#string

Frank Goebel

http://www.w3.org/2001/XMLSchema#string

Griet Boogaerts

http://www.w3.org/2001/XMLSchema#string

Marie-Pierre P de Béthune

http://www.w3.org/2001/XMLSchema#string

Monika Peeters

http://www.w3.org/2001/XMLSchema#string

Richard Hoetelmans

http://www.w3.org/2001/XMLSchema#string

P304

1721-1726

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.AIDS.0000242818.65215.BD

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16931936

http://www.w3.org/2001/XMLSchema#string